Supplementary data for the article:

Savić, N. D.; Milivojevic, D. R.; Glišić, B. D.; Ilic-Tomic, T.; Veselinovic, J.; Pavic, A.; Vasiljevic, B.; Nikodinovic-Runic, J.; Djuran, M. I. A Comparative Antimicrobial and Toxicological Study of Gold(III) and Silver(i) Complexes with Aromatic Nitrogen-Containing Heterocycles: Synergistic Activity and Improved Selectivity Index of Au(III)/Ag(i) Complexes Mixture. *RSC Advances* **2016**, *6* (16), 13193–13206. https://doi.org/10.1039/c5ra26002g

Electronic Supplementary Information

A comparative antimicrobial and toxicological study of gold(III) and silver(I) complexes with aromatic nitrogen-containing heterocycles: Synergistic activity and improved selectivity index of Au(III)/Ag(I) complexes mixture

Nada D. Savić,<sup>a</sup> Dusan R. Milivojevic,<sup>b</sup> Biljana Đ. Glišić,<sup>\*a</sup> Tatjana Ilic-Tomic,<sup>b</sup> Jovana Veselinovic,<sup>c</sup> Aleksandar Pavic,<sup>b</sup> Branka Vasiljevic,<sup>b</sup> Jasmina Nikodinovic-Runic<sup>\*b</sup> and Miloš I. Djuran<sup>a</sup>

<sup>a</sup>Department of Chemistry, Faculty of Science, University of Kragujevac, R. Domanovića
12, PO Box 60, 34000 Kragujevac, Serbia
<sup>b</sup>Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode
Stepe 444a, 11000 Belgrade, Serbia
<sup>c</sup> Faculty of Medicine, Department of Chemistry, University of Niš, 18000 Niš, Serbia

\*Corresponding authors. Tel.: +381 34 300 251; fax: +381 34 335 040 (B. D. Glišić); Tel.: +381 11 397 6034; fax: +381 11 397 5808 (J. Nikodinovic-Runic).

*E-mail address:* <u>bglisic@kg.ac.rs</u> (B. Đ. Glišić); <u>jasmina.nikodinovic@gmail.com</u> (J. Nikodinovic-Runic).

### Abstract

Five aromatic nitrogen-containing heterocycles, pyridazine (pydz, 1), pyrimidine (pm, 2), pyrazine (pz, 3), quinoxaline (qx, 4) and phenazine (phz, 5) have been used for the synthesis of gold(III) and silver(I) complexes. In contrast to the mononuclear Au1-5 complexes all having square-planar geometry, the corresponding Ag1-5 complexes have been found to be polynuclear and of different geometries. Complexes Au1-5 and Ag1-5, along with K[AuCl<sub>4</sub>], AgNO<sub>3</sub> and N-heterocyclic ligands used for their synthesis, were evaluated by in vitro antimicrobial studies against a panel of microbial strains that lead to many skin and soft tissue, respiratory, wound and nosocomial infections. All tested complexes exhibited excellent to good antibacterial activity with minimal inhibitory (MIC) values in the range of 2.5 to 100 µg mL<sup>-1</sup> against the investigated strains. The complexes were particularly efficient against pathogenic *Pseudomonas aeruginosa* (MIC =  $2.5-30 \mu g$ mL<sup>-1</sup>) and had a marked ability to disrupt clinically relevant biofilms of strains with high inherent resistance to antibiotics. Moreover, the Au1-4 and Ag1-5 complexes exhibited pronounced ability to competitively intercalate double stranded bacterial genomic DNA of P. aeruginosa, which was demonstrated by gel electrophoresis techniques and supported by molecular docking into the DNA major groove. Antiproliferative effect on the normal human lung fibroblast cell line MRC5 has also been evaluated in order to determine therapeutic potential of Au1-5 and Ag1-5 complexes. Since the investigated gold(III) complexes showed much lower negative effects on the viability of the MRC5 cell line than their silver(I) analogues and slightly lower antimicrobial activity against the investigated strains, the combination approach to improve their pharamacological profiles was applied. Synergistic antimicrobial effect and the selectivity index of 10 were achieved for the selected gold(III)/silver(I) complexes mixtures, as well as higher P. aeruginosa PAO1 biofilm disruption activity, and improved toxicity profile towards zebrafish embryos, in

comparison to the single complexes. To the best of our knowledge, this is the first report on synergistic activity of gold(III)/silver(I) complexes mixtures and it could have an impact on development of new combination therapy methods for the treatment of multi-resistant bacterial infections.

*Keywords*: Silver(I) complexes; Gold(III) complexes; Antibacterial activity; Cytotoxicity; *Danio rerio*; Synergism

### **TABLE OF CONTENTS**

**Fig. S1** Air/light stability of **Au1-5** and **Ag1-5** complexes. Sterile cellulose discs S5 were impregnated with these complexes and exposed to air and light within 96 h.

**Fig. S2** Computational docking model illustrating interactions between DNA and S6 all studied Au(III) complexes.

**Fig. S3** Computational docking model illustrating interactions between DNA and S7 all studied Ag(I) complexes.

**Fig. S4** Representative fluorescent microscopy image of a *P. aeruginosa* PAO1 S8 mature biofilm, treated with mixture of **Au1/Ag1** (8:1) and **Au3/Ag1** (6.4:1). Bar represents 10 μm.

**Table S1** Comparison of MIC values (µg mL<sup>-1</sup>) of the investigated gold(III) and S9 silver(I) compounds in different incubation media

**Table S2** Effect percentages for abnormal morphological characteristics evaluatedS10in the zebrafish teratogenicity assay at 114 hpf

**Table S3** Lethal and teratogenic effects observed in zebrafish (Danio rerio)embryos at different hours post fertilization (hpf)

# Electronic Supplementary Information



**Fig. S1** Air/light stability of **Au1-5** and **Ag1-5** complexes. Sterile cellulose discs were impregnated with these complexes and exposed to air and light within 96 h.



Fig. S2 Computational docking model illustrating interactions between DNA and all studied Au(III) complexes.



**Fig. S3** Computational docking model illustrating interactions between DNA and all studied Ag(I) complexes.



**Fig. S4** Representative fluorescent microscopy image of a *P. aeruginosa* PAO1 mature biofilm, treated with mixture of **Au1/Ag1** (8:1) and **Au3/Ag1** (6.4:1). Bar represents 10 μm.

Table S1 Comparison of MIC values (µg mL<sup>-1</sup>) of the investigated gold(III) and silver(I)

	Pseudomonas aeruginosa PAO1						
Complex	LB	No serum	Serum				
Au1	$10 \pm 1$	$10 \pm 0.3$	$20 \pm 0.8$				
Ag1	$2.5 \pm 0.1$	$5 \pm 0.1$	$5 \pm 0.1$				
Au2	$15 \pm 1$	$15.6 \pm 1$	$31.2 \pm 1$				
Ag2	$2.5 \pm 0.1$	$5 \pm 0.1$	$10 \pm 0.1$				
Au3	$8 \pm 0.5$	$15.6 \pm 0.5$	$15.6 \pm 1$				
Ag3	$7.8 \pm 0.5$	$10 \pm 0.4$	$10 \pm 0.6$				
Au4	$12.5 \pm 0.5$	$15.6 \pm 0.5$	$31.2 \pm 0.8$				
Ag4	$15.6 \pm 0.5$	$15.6 \pm 0.5$	$15.6 \pm 0.5$				
Au5	$30 \pm 4$	$62.5 \pm 6$	$62.5 \pm 6$				
Ag5	$7.8 \pm 4$	$15.6 \pm 4$	$15.6 \pm 4$				
K[AuCl <sub>4</sub> ]	$8 \pm 0.5$	$15.6 \pm 0.5$	$31.2 \pm 1$				
AgNO <sub>3</sub>	$3.1 \pm 0.1$	$5 \pm 0.1$	$5 \pm 0.1$				

compounds in different incubation media

Compound concentration	Dead embryos <sup>a</sup>	Teratogenic embryos <sup>a</sup>	Normal embryos <sup>a</sup>	Growth retardation <sup>b</sup>	Notochord <sup>b</sup>	Eyes <sup>b</sup>	Otoliths <sup>b</sup>	Pericardial edema <sup>b</sup>	Yolk edema <sup>b</sup>	Heart beat <sup>b</sup>	Blood circulation <sup>b</sup>	Unhatched <sup>b</sup>	Head malformation <sup>c</sup>	Skeletal deformities <sup>c</sup>
Ag1														
50 μg/mL	100.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-
25 μg/mL	100.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-
10 µg/mL	95.83	4.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	100.00
5 μg/mL	25.00	75.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	100.00
Au1														
50 μg/mL	100.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-
25 μg/mL	58.33	41.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	0.00	0.00	0.00
10 μg/mL	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	0.00	0.00	0.00	0.00
5 μg/mL	0.00	8.33	91.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Au3														
50 μg/mL	100.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	
25 μg/mL	95.83	4.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	n.d.	n.d.
10 µg/mL	62.50	37.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.00	n.d.	n.d.
5 μg/mL	8.33	12.50	79.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.64
Au1/Ag1 8:1														
50 μg/mL	100.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-
25 μg/mL	62.50	0.00	37.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
10 µg/mL	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5 μg/mL	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Au3/Ag1 6.4:1														
50 μg/mL	100.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-
25 μg/mL	62.50	0.00	37.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
10 µg/mL	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5 μg/mL	0.00	0.00	100.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Table S2 Effect percentages for abnormal morphological characteristics evaluated in the zebrafish teratogenicty assay at 114 hpf

Abbreviation used: (hpf) hours post fertilization; (-) data not available due to 100% mortality; (n.d.) not detected.

<sup>a</sup> Percentage of mortality based on all eggs.
 <sup>b</sup> Percentage of teratogenic effect based on all alive embryos at the time of assessment.

<sup>c</sup> Percentage of teratogenic effect based on all alive hatched embryos at the time of assessment.

## Table S3 Lethal and teratogenic effects observed in zebrafish (Danio rerio) embryos at

Category	Developmental endpoints	Exposure time (hpf)				
		24	48	72	96 /114	
Lethal effect	Egg coagulation <sup>a</sup>	•	•	•	•	
	No somite formation	•	•	•	•	
	Tail not detached	•	•	•	•	
	No heartbeat		•	•	•	
Teratogenic effect	Malformation of head	•	•	•	•	
-	Malformation of eyes <sup>b</sup>	•	•	•	•	
	Malformation of sacculi/otolithsc	•	•	•	•	
	Malformation of chorda	•	•	•	•	
	Malformation of tail <sup>d</sup>	•	•	•	•	
	Scoliosis	•	•	•	•	
	Heart beat frequency		•	•	•	
	Blood circulation		•	•	•	
	Pericardial edema	•	•	•	•	
	Yolk edema		•	•	•	
	Yolk deformation	•	•	•	•	
	Growth retardation <sup>e</sup>	•	•	•	•	

### different hours post fertilization (hpf)

<sup>a</sup> No clear organs structure is recognized.

<sup>b</sup> Malformation of eyes was recorded for the retardation in eye development and abnormality in shape and size.

<sup>c</sup> Presence of no, one or more than two otoliths per sacculus, as well as reduction and enlargement of otoliths and/or sacculi (otic vesicles).

<sup>d</sup> Tail malformation was recorded when the tail was bent, twisted or shorter than to control embryos as assessed by optical comparation.

<sup>e</sup> Growth retardation was recorded by comparing with the control embryos in development or size (before hatching, at 24 hpf and 48 hpf) or in a body length (after hatching, at and onwards 72 hpf) using by optical comparation using a inverted microscope (CKX41; Olympus, Tokyo, Japan).